A229500 Stock Overview
Engages in the development and sale of drugs to treat metabolic diseases in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NovMetaPharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩6,480.00 |
| 52 Week High | ₩22,900.00 |
| 52 Week Low | ₩4,910.00 |
| Beta | 0 |
| 11 Month Change | 3.02% |
| 3 Month Change | n/a |
| 1 Year Change | -65.89% |
| 33 Year Change | -75.91% |
| 5 Year Change | -84.91% |
| Change since IPO | -35.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| A229500 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -3.6% | 3.7% | 1.3% |
| 1Y | -65.9% | 13.3% | 8.4% |
Return vs Industry: A229500 underperformed the KR Pharmaceuticals industry which returned 13.3% over the past year.
Return vs Market: A229500 underperformed the KR Market which returned 8.4% over the past year.
Price Volatility
| A229500 volatility | |
|---|---|
| A229500 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.0% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A229500's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A229500's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Sun-Wook Hwang | www.novmeta.com |
NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic diseases in South Korea. The company is developing NovDB2, a type 2 diabetes medication; NovOB, an anti-obesity medication; NovRD, a chronic kidney disease medication; NovFS, a fibrosis medication; and NovRF, a retroperitoneal fibrosis medication. It also develops drugs for inflammatory bowel; viral; vascular; bone loss; bone loss; cognitive impairment; Alzheimer’s; acute pancreatitis; degenerative brain; and liver cancer diseases, as well as cytokine inhibitor and exercise performance enhancement products.
NovMetaPharma Co., Ltd. Fundamentals Summary
| A229500 fundamental statistics | |
|---|---|
| Market cap | ₩58.08b |
| Earnings (TTM) | ₩0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A229500 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A229500 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩0 |
| Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A229500 perform over the long term?
See historical performance and comparison